Sickle-cell thalassemia, unspecified, with crisis
ICD-10 D57.419 is a billable code used to indicate a diagnosis of sickle-cell thalassemia, unspecified, with crisis.
Sickle-cell thalassemia is a genetic blood disorder characterized by the presence of both sickle cell disease and thalassemia, leading to abnormal hemoglobin production. Patients with this condition experience episodes of pain crises due to vaso-occlusive events, which occur when sickle-shaped red blood cells obstruct blood flow in small vessels. This can result in acute pain, organ damage, and increased risk of infections. The severity of symptoms can vary widely among individuals, influenced by the specific genetic mutations involved and the degree of thalassemia present. Management typically includes pain control, hydration, and sometimes blood transfusions or hydroxyurea therapy to reduce the frequency of crises. Understanding the underlying genetic factors is crucial for effective treatment and counseling, as both sickle cell disease and thalassemia are inherited conditions that can significantly impact a patient's quality of life.
Detailed patient history, including genetic testing results and frequency of crises.
Management of acute pain crises, routine monitoring of hemoglobin levels, and transfusion therapy.
Ensure accurate documentation of both sickle cell and thalassemia components for appropriate coding.
Comprehensive family history and genetic testing results to confirm diagnosis.
Counseling patients on inheritance patterns and implications for family members.
Documentation should reflect the genetic basis of the condition and any counseling provided.
Used during hospitalization for severe anemia due to sickle-cell thalassemia.
Document the indication for transfusion and patient response.
Hematology specialists should ensure that the transfusion is justified based on hemoglobin levels.
Sickle cell disease refers to a group of disorders characterized by sickle-shaped red blood cells, while sickle-cell thalassemia is a specific condition that includes both sickle cell disease and thalassemia, leading to a unique clinical presentation and management needs.
